| 摘要 |
The present invention for the first time identifies DHMEQ as a sensitizing agent for therapy (e.g., chemotherapy, hormonal therapy, radiotherapy and immunotherapy) of resistant and sensitive cells. The present invention therefore provides methods of treating drug and immunotherapy-sensitive cancers and treating drug and immunotherapy -resistant cancers with DHMEQ or structurally similar compounds either alone or in combination with chemotherapy, hormonal therapy, radiotherapy and immunotherapy agents.
|
